Clinical trial NCT02970487: Precisight® Intraocular Lens Implantation for Cataract Treatment
Official title: Refractive Outcome and Optimization of IOL-Constants After Implantation of the Precisight® Intraocular Lens.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cataract Senile
Keywords: cataract
Lead sponsor: InfiniteVision Optics
Sponsor class: INDUSTRY
Collaborators: name: Targomed
First posted: 2016-11-22
Enrollment: 96
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the refractive outcomes and optimize the clinical features of a new intraocular lens intended to treat the senile cataract.

Detailed description: InfiniteVision Optics has developed a new IOL system, the Precisight IOL. This IOL consists of a combination of two lenses: a base lens which is placed permanently into the capsular bag, and a front lens which sits on top of the base lens outside the capsular bag. The major advantage of this system is the adjustability of the primary IOL implantation which is done by front lens exchange. In case of either postoperative refractive adjustments or patient dissatisfaction with the visual performance, the front lens can be easily exchange by a less invasive surgery, avoiding a total IOL explantation. The implantation of the Precisight IOL is similar to the implantation of a traditional intraocular lens with no expected additional risk.

For all new IOLs, the IOL-constants are determined and provided by the manufacturer. They are calculated on the basis of eye models and clinical testing. In this study the biometric data of each patient's eye will be documented together with the implanted lens power and the postoperative stable refraction for calculation of the optimized IOL-constants.

In the present study, 125 subjects will be enrolled. Patients with a deviation from target refraction of more than 0.5 D spherical equivalent at the 2-3 month follow-up visit will undergo a secondary intervention for exchange of the front lens. These patients will be followed up for 1 year after front lens exchange.

Subjects will be screened during a pre-operative visit. Before the surgery visit, the subjected must have signed the Informed Consent Form.

After the surgery, patients will be followed up for one year. The visits will be scheduled at 1 day, 7-14 days, 2-3 months and 5-7 months and 1 year after surgery. Patients who underwent a surgery to exchange the front lens will be also followed up 1 day, 7-14 days, 2-3 months and 5-7 months and 1 year after the exchange surgery.

Investigator site staff will document the data in electronic Case Report Forms (eCRF). The data will be pseudonymized, i.e. only the year of birth and a code will be entered in the eCRF. Adverse events will be recorded in an eCRFs. Unexpected and serious adverse events are to be reported to the manufacturer.

Data cleaning will be done one month after last patient out and study report finished three months after last patient out. Subjects must be withdrawn from the study (i) at their own request, (ii) in case of intraoperative complication impacting the safety of the patient or (iii) in case of any postoperative complication if the continuation of the study has an impact on the safety of the patient. The study may terminate before completion if a high relative number of individual subject withdrawals due to the patient's requests and/or clinically relevant complications are observed. The IRB will be informed in due course accordingly.

The findings of this study will be published by the investigators in a scientific journal and presented at scientific meetings.

Eligibility criteria: Inclusion Criteria:

* Age-related bilateral cataract or one pseudophakic eye
* Visual acuity potential of the study eye of at least 0.63 (decimal)
* Expected postoperative astigmatism of ≤0.75 D in the study eye
* IOL power within available diopters
* Written informed patient consent regarding participation in the study and data protection

Exclusion Criteria:

* Visually significant corneal scars
* Ocular disorders - other than cataract - that could potentially cause future acuity losses to a level of 0.5 (decimal) or worse in the study eye
* Relevant concomitant ophthalmic diseases (such as pseudoexfoliation, angleclosure glaucoma, traumatic cataract and other co-morbidity that could affect capsular bag stability (e.g. Marfan syndrome)
* Participation of patient in other clinical trials (former participation is not an exclusion criterion)
* Any cataract condition that makes the assessment of retina status difficult
* Anyone with unstable systemic conditions or untreated systemic medical problems including but not limited to the following: Untreated diabetes, Cardiovascular untreated disease, Pulmonary untreated disease, Any untreated infection, Neuro-ophthalmologic diseases, Any allergy to the medications used during surgery

Primary outcomes:
measure: Change of the subjective refraction
timeFrame: 2 to 3 months, 5 to 7 months and 1 year after the investigational device implantation
Secondary outcomes:
measure: Best-corrected distance visual acuity
timeFrame: 1 day, 7 to 14 days, 2 to 3 months, 5 to 7 months and 1 year after the investigational device implantation
measure: Introcular lens (IOL) decentration and tilt
timeFrame: day of surgery, 2 to 3 months, 5 to 7 months and 1 year after the investigational device implantation
measure: Anterior chamber depth
timeFrame: pre-operative, 2 to 3 months, 5 to 7 months and 1 year after the investigational device implantation
measure: Adverse events
timeFrame: All follow up period (1 year)
measure: Assessment of investigator regarding handling and achievement of target refraction
timeFrame: Six months after investigational device implantation
Other outcomes:
Locations:
city: Makati
country: Philippines
facility: Peregrine Eye and Laser Institue
Study officials:
affiliation: Peregrine Eye and Laser Institute
name: Harvey S Uy, MD
role: PRINCIPAL_INVESTIGATOR
References: